F. Sirotnak

M. Kris, C. Azzoli, M. Ginsberg, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A novel class of genetic variants of the L1210 cell up-regulated for folate analogue transport inward. Isolation, characterization, and degree of metabolic instability of the system.

F. Sirotnak, C. Yang, D. M. Moccio, 1984, The Journal of biological chemistry.

Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: biological significance and implications for improved therapy of human cancer.

F. Sirotnak, 1985, Cancer research.

Carrier-mediated transport of folate compounds in L1210 cells. Initial rate kinetics and extent of duality of entry routes for folic acid and diastereomers of 5-methyltetrahydrohomofolate in the presence of physiological anions.

F. Sirotnak, D. Jacobsen, J. Barrueco, 1987, Biochemical pharmacology.

The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis and trans effects of inhibitors.

F. Sirotnak, D. F. O'Leary, 1991, Cancer research.

Alteration of folate analogue transport inward after induced maturation of HL-60 leukemia cells. Molecular properties of the transporter in an overproducing variant and evidence for down-regulation of its synthesis in maturating cells.

F. Sirotnak, C. Yang, J. Pain, 1992, The Journal of biological chemistry.

Edatrexate, an antifolate with antitumor activity: a review.

M. Kris, F. Sirotnak, S. Grant, 1993, Cancer investigation.

Ligand-directed Immunoaffinity Purification and Properties of the One-carbon, Reduced Folate Transporter

F. Sirotnak, K. Roy, J. Chiao, 1995, The Journal of Biological Chemistry.

Structural analysis of the human RFC-1 gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5' end heterogeneity.

F. Sirotnak, B. Tolner, K. Roy, 1998, Gene.

RFC-1 Gene Expression Regulates Folate Absorption in Mouse Small Intestine*

F. Sirotnak, K. Roy, B. Tolner, 1997, The Journal of Biological Chemistry.

Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.

G. Schwartz, M. Motwani, F. Sirotnak, 2003, Molecular cancer therapeutics.

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.

M. Kris, V. Miller, J. Chen, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

V. Seshan, C. Rudin, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Studies with ZD1839 in preclinical models.

F. Sirotnak, 2003, Seminars in oncology.

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

A. Zelenetz, D. Mould, S. Horwitz, 2007, British journal of haematology.

Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

G. Schwartz, M. Motwani, F. Sirotnak, 2002, Cancer research.

Molecular cloning of the murine cMOAT ATPase.

F. Sirotnak, J. Chen, F. Fritz, 2000, Biochimica et biophysica acta.

The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

J. Teruya-Feldstein, M. Gonen, F. Sirotnak, 2006, Clinical Cancer Research.

Adaptive regulation of intestinal folate uptake: effect of dietary folate deficiency.

S. Rubin, F. Sirotnak, L. Matherly, 2000, American journal of physiology. Cell physiology.

Hydrolytic cleavage of methotrexate gamma-polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse.

F. Sirotnak, D. Priest, L. J. Goutas, 1986, Cancer research.

Regulation of transcription of the murine gamma-glutamyl hydrolase gene. Delineation of core promoter A and the role of LYF-1, E2F and ETS-1 in determining tumor-specific expression.

F. Sirotnak, J. Chen, N. Masumoto, 2002, Gene.

Growth inhibitory, transport and biochemical properties of the gamma-glutamyl and gamma-aspartyl peptides of methotrexate in L1210 leukemia cells in vitro.

J. Montgomery, F. Sirotnak, P. Chello, 1978, Biochemical pharmacology.

Altered molecular properties of tubulin in a multidrug‐resistant variant of Chinese hamster cells selected for resistance to vinca alkaloids

F. Sirotnak, C. Yang, J. L. Biedler, 1988, Journal of cellular physiology.

Markedly altered membrane transport and intracellular binding of vincristine in multidrug‐resistant Chinese hamster cells selected for resistance to vinca alkaloids

F. Sirotnak, C. Yang, J. L. Biedler, 1986, Journal of cellular physiology.

Posttranscriptionally Mediated Decreases in Folylpolyglutamate Synthetase Gene Expression in Some Folate Analogue-resistant Variants of the L1210 Cell

F. Sirotnak, M. Egan, K. Roy, 1997, The Journal of Biological Chemistry.

Organization and Alternate Splicing of the Murine Folylpolyglutamate Synthetase Gene

F. Sirotnak, Krishnendu Roy, Kenji Mitsugi, 1996, The Journal of Biological Chemistry.

Rapid Decline in Folylpolyglutamate Synthetase Activity and Gene Expression during Maturation of HL-60 Cells

B. Rumberger, F. Sirotnak, B. Rumberger, 1995, Journal of Biological Chemistry.

Different Antifolate-resistant L1210 Cell Variants with either Increased or Decreased Folylpolyglutamate Synthetase Gene Expression at the Level of mRNA Transcription (*)

F. Sirotnak, K. Roy, B. Shane, 1995, The Journal of Biological Chemistry.

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

M. Kris, C. Azzoli, E. Venkatraman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

V. Seshan, A. Zelenetz, D. Mould, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase ‘2-1-2’ study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

D. Mould, S. Horwitz, F. Sirotnak, 2007 .

Contrasting effects of oncogene expression on two carrier‐mediated systems internalizing folate compounds in Fisher rat 3T3 cells

F. Sirotnak, J. Chiao, J. Chiao, 2000, Journal of cellular physiology.

New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties

F. Sirotnak, D. M. Moccio, L. J. Goutas, 2004, Cancer Chemotherapy and Pharmacology.

Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.

F. Sirotnak, D. M. Moccio, P. Chello, 1982, Cancer treatment reports.

New folate analogs of the 10-deaza-aminopterin series

F. Sirotnak, D. M. Moccio, L. J. Goutas, 2004, Cancer Chemotherapy and Pharmacology.

Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.

A. Zelenetz, M. Fleisher, S. Horwitz, 2005 .

APhase 1 Study of Pralatrexate in Combinationwith Paclitaxel or Docetaxel in Patients with Advanced SolidTumors

M. Kris, C. Azzoli, E. Venkatraman, 2007 .

A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors

M. Kris, C. Azzoli, E. Venkatraman, 2007, Clinical Cancer Research.

Transcription of the mouse RFC-1 gene encoding a folate transporter. Multiplicity and properties of promoters with minimum requirements for their basal activity.

F. Sirotnak, B. Tolner, K. Roy, 1999, Gene.

Despite some expression of folate receptor alpha in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated.

V. Rusch, F. Sirotnak, N. Khokhar, 2002, The Journal of thoracic and cardiovascular surgery.

Production of Lactic Acid and an Iodine Staining Substance by Bovine Rumen Bacteria

F. Sirotnak, R. Doetsch, R. Q. Robinson, 1955 .

The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD 1839 Selectively Potentiates Radiation Response of Human Tumors in Nude Mice , with a Marked Improvement in Therapeutic Index 1

M. Kris, V. Miller, F. Sirotnak, 2003 .

Markedly Decreased Binding of Vincristine to Tubulin in Vinca Alkaloid-Resistant Chinese Hamster Cells Is Associated with Selective Overexpression of α and β Tubulin Isoforms

K. Danenberg, F. Sirotnak, P. Danenberg, 2000 .

Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo.

F. Sirotnak, D. M. Moccio, L. J. Goutas, 1981, Cancer research.

Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.

F. Sirotnak, F. Schmid, J. Degraw, 1989, Cancer research.

GENETIC MODIFICATION OF THE STRUCTURE AND AMOUNT OF DIHYDROFOLATE REDUCTASE IN AMETHOPTERIN-RESISTANT DIPLOCOCCUS PNEUMONIAE.

D. Hutchison, F. Sirotnak, G. Donati, 1964, The Journal of biological chemistry.

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.

M. Kris, V. Miller, L. Krug, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synthesis and Antitumor Activity of 10‐Propargyl‐10‐deazaaminopterin ( VII).

F. Sirotnak, J. Degraw, J. R. Piper, 1994 .

Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.

F. Sirotnak, J. Degraw, J. R. Piper, 1993, Journal of medicinal chemistry.

New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.

F. Sirotnak, F. Schmid, J. Degraw, 1985, Cancer treatment reports.

Cloning of mouse gamma-glutamyl hydrolase in the form of two cDNA variants with different 5' ends and encoding alternate leader peptide sequences.

F. Sirotnak, K. Roy, J. Galivan, 1998, Gene.

Differential permeability and the basis for selective activity during methotrexate therapy of the l1210 leukemia. Abstr.

F. Sirotnak, R. C. Donsbach, 1973 .

Correlates of folate analog transport, pharmacokinetics and selective antitumor action

F. Sirotnak, 1980 .

Net accumulation of methotrexate by carrier-mediated transport in different munine tumor cells in vitro exhibits a positive correlation with the relative drug phanmacokinetics and therapeutic responsiveness in these tumors in vivo. The transport of methotrexate by Sarcoma 180, Ehrlich carci

F. Sirotnak, R. C. Donsbach, 2006 .

Structural preferences among folate compounds and their analogues for ATPase-mediated efflux by inside-out plasma membrane vesicles derived from L1210 cells.

F. Sirotnak, S. Schlemmer, 1995, Biochemical pharmacology.

Further studies stereospecificity at carbon 6 for membrane transport of tetrahydrofolates. Diastereoisomers of 5-methyltetrahydrofolates as competitive inhibitors of transport of methotrexate in L1210 cells.

F. Sirotnak, P. Chello, R. Kisliuk, 1982, Biochemical pharmacology.

Two different effects of mutation on the binding of folate antagonists by a microbial dihydrofolate reductase.

F. Sirotnak, 1973, Biochimica et biophysica acta.

Sequential Biochemical Alteration to Antifolate Resistance in L121O Leukaemia

D. Hutchison, F. Sirotnak, M. Sargent, 1967, Nature.

Genetically Alterable Transport of Amethopterin in Diplococcus pneumoniae I. Physiological Properties and Kinetics of the Wild-type System

D. Hutchison, F. Sirotnak, M. Sargent, 1967 .

Genetically Alterable Transport of Amethopterin in Diplococcus pneumoniae II. Impairment of the System Associated with Various Mutant Genotypes

D. Hutchison, F. Sirotnak, M. Sargent, 1967, Journal of bacteriology.

Evidence for a genetic alteration of dihydrofolate reductase associated with amethopterin resistance in Diplococcus pneumoniae.

D. Hutchison, F. Sirotnak, G. Donati, 1964, Biochemical and biophysical research communications.

Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.

F. Sirotnak, D. M. Moccio, D. M. Dorick, 1976, Cancer research.

Evidence for the facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Basic properties and specificity for polyglutamate chain length.

F. Sirotnak, J. Barrueco, 1991, The Journal of biological chemistry.

A basis for the difference in toxicity of methotrexate, aminopterin and methasquin in mice.

F. Sirotnak, R. C. Donsbach, 1975, Biochemical pharmacology.

Thymidylate synthetase from Diplococcus pneumoniae, properties and inhibition by folate analogs.

F. Sirotnak, R. McCuen, 1975, Biochimica et biophysica acta.

Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.

F. Sirotnak, F. Schmid, G. Otter, 1993, Cancer research.

Energy-dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles.

F. Sirotnak, S. Schlemmer, 1992, The Journal of biological chemistry.

Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro.

F. Sirotnak, Y. She, B. Cassileth, 2004, International immunopharmacology.

FOLIC ACID DERIVATIVES SYNTHESIZED DURING GROWTH OF DIPLOCOCCUS PNEUMONIAE

D. Hutchison, F. Sirotnak, G. Donati, 1963, Journal of bacteriology.

Studies on the in vivo synthesis of methotrexate polyglutamates and their efflux properties in normal, proliferative, and neoplastic mouse tissues.

F. Sirotnak, R. Poser, 1983, Advances in experimental medicine and biology.

Additional organizational features of the murine γ-glutamyl hydrolase gene

F. Sirotnak, N. Masumoto, T. Esaki, 2001 .

Synthesis and antifolate properties of 10-alkyl-5,10-dideaza analogues of methotrexate and tetrahydrofolic acid.

F. Sirotnak, R. Kisliuk, Y. Gaumont, 1990, Journal of medicinal chemistry.

Chemical synthesis and biological activities of 5-deazaaminopterin analogues bearing substituent(s) at the 5- and/or 7-position(s).

T. Chou, F. Sirotnak, K. Watanabe, 1988, Journal of medicinal chemistry.

9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.

T. Chou, F. Sirotnak, K. Watanabe, 1995, Journal of medicinal chemistry.

Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.

J. Montgomery, F. Sirotnak, R. Kisliuk, 1986, Journal of medicinal chemistry.

The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract.

C. Fankhauser, K. Rose, F. Sirotnak, 1997, Journal of natural products.

A new human peptide deformylase inhibitable by actinonin.

D. Scheinberg, Yueming Li, F. Sirotnak, 2003, Biochemical and biophysical research communications.

Membrane transport and the antineoplastic action of nucleoside analogues

F. Sirotnak, J. Barrueco, 2004, Cancer and Metastasis Reviews.

Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.

R. W. Brockman, F. Sirotnak, D. Jacobsen, 1987, Cancer research.

Specificity of systems mediating transport of adenosine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells.

J. Montgomery, F. Sirotnak, P. Chello, 1983, Cancer research.

Amino Acid Metabolism of Bovine Rumen Bacteria

R. E. Brown, F. Sirotnak, R. Doetsch, 1953 .

The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

M. Gonen, G. Schwartz, C. Jung, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Aspartate Dissimilation Reactions of Rumen Bacteria

F. Sirotnak, R. Doetsch, R. Q. Robinson, 1954 .

Folate analog transport by plasma membrane vesicles isolated from L1210 leukemia cells.

F. Sirotnak, C. Yang, P. Chello, 1979, The Journal of biological chemistry.

Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.

D. Scheinberg, F. Sirotnak, Y. She, 2004, The Journal of clinical investigation.

Analog specific aberrancies in antifolate inhibition of L1210 cell dihydrofolate reductase.

J. Montgomery, F. Sirotnak, D. M. Moccio, 1980, Biochemical pharmacology.

DIHYDROFOLATE REDUCTASE IN GENOTYPICALLY DISTINGUISHABLE AMETHOPTERIN-RESISTANT DIPLOCOCCUS PNEUMONIAE.

D. Hutchison, F. Sirotnak, G. Donati, 1964, The Journal of biological chemistry.

On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia.

D. Hutchison, F. Sirotnak, S. Kurita, 1968, Cancer research.

Absorption of deoxyribonucleic acid by mouse lymphoma cells.

F. Sirotnak, D. Hutchinson, 1959, Biochimica et biophysica acta.

Synthesis and antifolate activity of 8,10‐dideazaminopterin

F. Sirotnak, R. Kisliuk, Y. Gaumont, 1982 .

Synthesis and evaluation of 8,10-dideazatetrahydrofolic acid and derivatives

F. Sirotnak, R. Kisliuk, Y. Gaumont, 1993 .

Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.

F. Sirotnak, R. Kisliuk, Y. Gaumont, 1989, Cancer research.

Analogs of tetrahydrofolate directed at folate-dependent purine biosynthetic enzymes. Characteristics of mediated entry and transport-related resistance in L1210 cells for 5,10-dideazatetrahydrofolate and two 10-alkyl derivatives.

F. Sirotnak, J. Degraw, J. R. Piper, 1988, Biochemical pharmacology.

Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.

J. Montgomery, F. Sirotnak, R. Kisliuk, 1988, Journal of medicinal chemistry.

Initial rate kinetics and evidence for duality of mediated transport of adenosine, related purine nucleosides, and nucleoside analogues in L1210 cells.

J. Montgomery, F. Sirotnak, C. Yang, 1983, Cancer research.

Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action.

B. Rumberger, F. Sirotnak, J. Barrueco, 1990, Cancer research.

Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo.

F. Sirotnak, P. Chello, R. Poser, 1981, Cancer research.

Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.

F. Sirotnak, D. M. Moccio, D. M. Dorick, 1978, Cancer research.

Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.

F. Sirotnak, D. M. Moccio, D. M. Dorick, 1976, Cancer research.

Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.

F. Sirotnak, R. C. Donsbach, 1973, Cancer research.

Stereochemical characteristics of the folate-antifolate transport mechanism in L1210 Leukemia cells.

F. Sirotnak, R. C. Donsbach, 1974, Cancer research.

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

M. Kris, H. Scher, V. Miller, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Organization and structure of the mouse gamma-glutamyl hydrolase gene and the functional identification of its promoter.

F. Sirotnak, N. Masumoto, J. Chen, 1999, Gene.

Proliferation-dependency of folylpolyglutamyl synthetase activity in maturating luminal epithelial cells of mouse small intestine.

F. Sirotnak, J. Galivan, T. Johnson, 1988, Biochemical pharmacology.

F. Sirotnak, D. M. Moccio, L. L. Samuels, 1985, Cancer research.

F. Sirotnak, C. Yang, D. M. Moccio, 1984, Cancer research.

Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice.

F. Sirotnak, D. M. Moccio, D. M. Dorick, 1978, Cancer treatment reports.

Increased dihydrofolate reductase synthess in Diplococcus pneumoniae following translatable alteration of the structural gene. I. Genotype derivation and recombinational analyses.

F. Sirotnak, S. Hachtel, 1969, Genetics.

ALTERATION IN TRANSFORMABILITY OF DIPLOCOCCUS PNEUMONIAE AFTER THE ACQUISITION OF GENETIC DETERMINANTS INDUCING RESISTANCE TO ERYTHROMYCIN

D. Hutchison, F. Sirotnak, R. B. Lunt, 1963, Journal of bacteriology.

Syntheses and evaluation as antifolates of MTX analogues derived from 2, omega-diaminoalkanoic acids.

J. Montgomery, F. Sirotnak, F. Schmid, 1985, Journal of medicinal chemistry.

Syntheses of alpha- and gamma-substituted amides, peptides, and esters of methotrexate and their evaluation as inhibitors of folate metabolism.

J. Montgomery, F. Sirotnak, P. Chello, 1982, Journal of medicinal chemistry.

Kinetic Correlates of MethotrexateTransportand Therapeutic Responsivenessin Murine Tumor

F. Sirotnak, R. C. Donsbach, 1976 .

Mutagenicity of derivatives of the oncogenic purine N-oxides.

F. Sirotnak, R. McCuen, G. Stöhrer, 1974, Cancer research.

Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events

W. Gerald, H. Scher, F. Sirotnak, 2004, Molecular carcinogenesis.

Uptake of methotrexate, aminopterin, and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine.

D. Hutchison, F. Sirotnak, J. Sodergren, 1973, Cancer research.

Carrier-mediated membrane transport of folates in mammalian cells.

F. Sirotnak, B. Tolner, 1999, Annual review of nutrition.

Two promoters regulate transcription of the mouse folylpolyglutamate synthetase gene three tightly clustered Sp1 sites within the first intron markedly enhance activity of promoter B.

F. Sirotnak, K. Roy, J Chen, 2000, Gene.

GENETIC STUDIES ON AMETHOPTERIN RESISTANCE IN DIPLOCOCCUS PNEUMONIAE

D. Hutchison, F. Sirotnak, R. B. Lunt, 1960, Journal of bacteriology.

Additional Organizational Features of the Murine Folylpolyglutamate Synthetase Gene

F. Sirotnak, Krishnendu Roy, Kenji Mitsugi, 1997, The Journal of Biological Chemistry.

Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.

T. Chou, F. Sirotnak, X. Kong, 1992, Molecular pharmacology.

Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.

M. Waltham, B. Schweitzer, J. Bertino, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Marked enhancement of diplococcus pneumoniae competence for transformation by tryptic peptides of casein.

F. Sirotnak, 1971, Biochemical and biophysical research communications.

Extentof the Requirementfor FolateTransportby L 1210 Cells for Growthand Leukemogenesisin V / Vo 1

F. Sirotnak, L. S. Mines, L. Goa, 2006 .

Advances in Brief Drg 1 , a Novel Target for Modulating Sensitivity to CPT-11 in Colon Cancer Cells 1

G. Schwartz, M. Motwani, F. Sirotnak, 2002 .

Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice

F. Sirotnak, D. Priest, M. Bunni, 2004, Cancer Chemotherapy and Pharmacology.

10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.

F. Sirotnak, F. Schmid, J. Degraw, 1987, NCI monographs : a publication of the National Cancer Institute.

Extracellular recovery of methotrexate-polyglutamates following efflux from L1210 leukemia cells.

F. Sirotnak, P. Chello, R. Poser, 1980, Biochemical pharmacology.

Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro

T. Chou, F. Sirotnak, Ting-Chao Chou, 1995, Cancer Chemotherapy and Pharmacology.

Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine

F. Sirotnak, G. Otter, 2004, Cancer Chemotherapy and Pharmacology.

Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro

T. Chou, F. Sirotnak, Ting-Chao Chou, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.

M. Kris, D. Pfister, K. Pisters, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression and Differential Polarization of the Reduced-folate Transporter-1 and the Folate Receptor α in Mammalian Retinal Pigment Epithelium*

V. Ganapathy, F. Sirotnak, P. Prasad, 2000, The Journal of Biological Chemistry.

Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.

M. Kris, H. Scher, V. Miller, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5' end heterogeneity.

F. Sirotnak, M. Dabrowska, 2004, Gene.

THE DISTRIBUTION OF MUTATIONAL SITES AFFECTING RESISTANCE TO AMETHOPTERIN IN DIPLOCOCCUS PNEUMONIAE.

D. Hutchison, F. Sirotnak, R. B. Lunt, 1964, Genetics.

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

M. Kris, C. Azzoli, N. Rosen, 2007, Cancer Chemotherapy and Pharmacology.

Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia.

F. Sirotnak, D. M. Moccio, P. Chello, 1979, Cancer treatment reports.

Different effects of vincristine on methotrexate uptake by L1210 cells and mouse intestinal epithelia in vitro and in vivo.

F. Sirotnak, P. Chello, D. M. Dorick, 1979, Cancer research.

Optimum scheduling during combination chemotherapy of murine leukemia

J. Montgomery, F. Sirotnak, C. Temple, 2004, Cancer Chemotherapy and Pharmacology.

Sequential combination of methotrexate and vindesine in previously treated children with acute leukemia. A phase I-II study.

F. Sirotnak, D. Miller, C. Tan, 1984, American Journal of Clinical Oncology.

Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.

F. Sirotnak, P. Chello, 1981, Cancer treatment reports.

Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.

M. Kris, T. Chou, V. Miller, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

A. Zelenetz, D. Mould, C. Moskowitz, 2006 .

Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: Evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles

M. Dembo, F. Sirotnak, C. Yang, 2005, The Journal of Membrane Biology.

The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells.

F. Sirotnak, R. C. Donsbach, 1974, Cancer research.

F. Sirotnak, A. Yagoda, D. M. Moccio, 1984, Cancer research.

Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.

J. Montgomery, F. Sirotnak, D. M. Moccio, 1982, Cancer research.

Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.

F. Sirotnak, P. Chello, D. M. Dorick, 1977, Cancer research.

Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell.

F. Sirotnak, R. C. Donsbach, 1972, Cancer research.

Gel filtration properties of mutant and wild-type dihydrofolate reductase from Diplococcus pneumoniae.

D. Hutchison, F. Sirotnak, 1965, Biochemical and biophysical research communications.

Organization, structure and alternate splicing of the murine RFC-1 gene encoding a folate transporter.

F. Sirotnak, B. Tolner, K. Roy, 1997, Gene.

Hyperproduction mutation in the dihydrofolate reductase gene of Diplococcus pneumoniae: some effects on synthesis correlate with the presence of a modified enzyme form.

F. Sirotnak, 1973, Biochimica et biophysica acta.

Hyperproduction of dihydrofolate reductase in Diplococcus pneumoniae after mutation in the structural gene. Evidence for an effect at the level of transcription.

F. Sirotnak, R. McCuen, 1973, Genetics.

Increased dihydrofolate reductase synthesis in Diplococcus pneumoniae following translatable alteration of the structural gene. II. Individual and dual effects on the properties and rate of synthesis of the enzyme.

W. A. Williams, F. Sirotnak, S. Hachtel, 1969, Genetics.

High Dihydrofolate Reductase Levels in Diplococcus pneumoniae After Mutation in the Structural Gene: Biochemical and Immunological Evidence for Increased Synthesis

F. Sirotnak, 1971, Journal of bacteriology.

Chromosomal localization of the murine RFC-1 gene encoding a folate transporter and its amplification in an antifolate resistant variant overproducing the transporter.

F. Sirotnak, B. Tolner, J. Chiao, 1998, Cancer genetics and cytogenetics.

Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.

F. Sirotnak, J. Barrueco, R. Poser, 1987, Cancer research.

Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux.

F. Sirotnak, D. M. Moccio, C. Young, 1981, Cancer research.

Schedule-dependent synergism of methotrexate and vincristine against l1210 leukemia. Abstr.

F. Sirotnak, P. Chello, D. M. Dorick, 1978 .

Antifolate transport in L1210 leukemia cells. Kinetic evidence for the non-identity of carriers for influx and efflux.

M. Dembo, F. Sirotnak, 1976, Biochimica et biophysica acta.

Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors.

F. Sirotnak, R. C. Donsbach, 1976, Cancer research.

Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.

F. Sirotnak, R. C. Donsback, 1975, Cancer research.

Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: Further evidence for separate influx and efflux systems with different energetic requirements

M. Dembo, F. Sirotnak, D. M. Moccio, 2005, The Journal of Membrane Biology.

Experimental chemotherapy with 5-arylpyrimidine antifolates: Further studies on toxicity and the responsiveness of ascitic, solid, and intracranial sarcoma 180 to DDMP and DDMP with citrovorum factor.

F. Sirotnak, D. M. Moccio, D. M. Dorick, 1977, Cancer treatment reports.

Experimental chemotherapy with 5-arylpyrimidine antifolates: preliminary studies on toxicity and responsiveness of sarcoma 180 to DDMP (NSC-19494) and DDMP with citrovorum factor (NSC-3590).

F. Sirotnak, D. M. Moccio, D. M. Dorick, 1976, Cancer treatment reports.

Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.

J. Montgomery, F. Sirotnak, F. Schmid, 1988, Cancer research.

Synthesis and Properties of 10-Benzylaminopterin

F. Sirotnak, P. Chello, M. A. Templeton, 1979 .

Specificity of the antifolate transport mechanism of mouse intestinal epithelia versus l1210 leukemia for n10 substituents. Abstr.

D. Hutchison, F. Sirotnak, P. Chello, 1976 .

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

M. Kris, H. Scher, N. Rosen, 2005, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of 10-Propargyl-10-deazaaminopterin , a New Antifolate 1

M. Kris, V. Miller, L. Krug, 2000 .

High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.

M. Kris, V. Miller, J. Rigas, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Increased dihydrofolate reductase synthesis in Diplococcus pneumoniae following translatable alteration of the structural gene. 3. Further evidence on the extent of genic involvement.

F. Sirotnak, 1970, Genetics.

A dissociable mutant form of diphydrofolate reductase from Diplococcus pneumoniae.

W. A. Williams, F. Sirotnak, 1970, Archives of biochemistry and biophysics.

Dual consequence of mutation in the dihydrofolate reductase gene of Diplococcus pneumoniae.

F. Sirotnak, 1969, Biochemical and biophysical research communications.

Purification and properties of mutant and wild-type dihydrofolate reductase from Diplococcus pneumoniae.

D. Hutchison, F. Sirotnak, 1966, The Journal of biological chemistry.

ToxÂ ¡ city , Elimination , and Metabolism of 10-Ethyl-lO-deazaaminopterin in Rats and Dogs 1

T. Chou, S. Sternberg, D. Niedzwiecki, 2006 .

Detection by high-performance liquid chromatography of methotrexate and its metabolites in tumor tissue from osteosarcoma patients treated with high-dose methotrexate/leucovorin rescue.

G. Rosen, F. Sirotnak, D. M. Moccio, 1984, Biochemical pharmacology.

SYNTHESES OF α‐ AND Γ‐SUBSTITUTED AMIDES, PEPTIDES, AND ESTERS OF METHOTREXATE AND THEIR EVALUATION AS INHIBITORS OF FOLATE METABOLISM

J. Montgomery, F. Sirotnak, P. Chello, 1982 .

Enhancing cytotoxic sensitivity of tumor cells to antifolates: another opportunity for gene therapy?

F. Sirotnak, 1999, Journal of the National Cancer Institute.

Facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Further characterization and evidence for a simple mobile carrier system with broad specificity for homo- or heteropeptides bearing a C-terminal glutamyl moiety.

F. Sirotnak, J. Barrueco, D. F. O'Leary, 1992, The Journal of biological chemistry.

Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells. Definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds.

F. Sirotnak, J. Barrueco, D. F. O'Leary, 1992, The Journal of biological chemistry.

Alteration of folate analogue transport following induced maturation of HL-60 leukemia cells. Early decline in mediated influx, relationship to commitment, and functional dissociation of entry and exit routes.

F. Sirotnak, D. Jacobsen, C. Yang, 1986, The Journal of biological chemistry.

Extent of the requirement for folate transport by L1210 cells for growth and leukemogenesis in vivo.

F. Sirotnak, L. J. Goutas, L. S. Mines, 1985, Cancer research.

Genetically alterable transport of amethopterin in Diplococcus pneumoniae. I. Physiological properties and kinetics of the wild-type system.

D. Hutchison, F. Sirotnak, M. Sargent, 1967, Journal of bacteriology.

Chromosomal mutation to drug resistance in bacteria.

F. Sirotnak, 1975, Antibiotics and chemotherapy.

Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

M. Gonen, G. Schwartz, C. Jung, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.

F. Sirotnak, F. Schmid, J. Degraw, 1987, Cancer treatment reports.

Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.

F. Sirotnak, H. Tagawa, R. Kisliuk, 1982, Journal of medicinal chemistry.

Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3.

F. Sirotnak, S. Schlemmer, 1994, The Journal of Biological Chemistry.

Synthesis and antifolate properties of 10-alkyl-8,10-dideazaminopterins.

F. Sirotnak, R. Kisliuk, Y. Gaumont, 1984, Journal of medicinal chemistry.

Phase II Trial of Pralatrexate (10-Propargyl-10-deazaaminopterin, PDX) in Patients with Unresectable Malignant Pleural Mesothelioma

M. Kris, E. Venkatraman, L. Krug, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention.

F. Sirotnak, 1987, NCI monographs : a publication of the National Cancer Institute.

E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells.

F. Sirotnak, M. Dabrowska, 2017, Acta biochimica Polonica.

2 F site in the essential promoter region does not confer S phase-specific transcription of the ABCC 10 gene in human prostate cancer cells

F. Sirotnak, M. Dabrowska, 2017 .

E 2 F site in the essential promoter region does not confer S phase-specific transcription of the ABCC 10 gene in human prostate cancer cells

F. Sirotnak, M. Dabrowska, 2017 .

P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine.

K. Scotto, F. Sirotnak, M. B. Meyers, 1991, Cancer Communications.

461 POSTER Early phase experience with pralatrexate (10-propargy l-10-deazaaminopterin [PRX]), a novel antifolate with high afnity forthe reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies

A. Zelenetz, D. Mould, S. Horwitz, 2006 .